198 related articles for article (PubMed ID: 31760080)
1. The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection.
Sapkota M; Marreddy RKR; Wu X; Kumar M; Hurdle JG
Anaerobe; 2020 Feb; 61():102129. PubMed ID: 31760080
[TBL] [Abstract][Full Text] [Related]
2. Structure and function of the Mur enzymes: development of novel inhibitors.
El Zoeiby A; Sanschagrin F; Levesque RC
Mol Microbiol; 2003 Jan; 47(1):1-12. PubMed ID: 12492849
[TBL] [Abstract][Full Text] [Related]
3.
Coullon H; Rifflet A; Wheeler R; Janoir C; Boneca IG; Candela T
J Biol Chem; 2018 Nov; 293(47):18040-18054. PubMed ID: 30266804
[TBL] [Abstract][Full Text] [Related]
4. Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection.
Srikhanta YN; Hutton ML; Awad MM; Drinkwater N; Singleton J; Day SL; Cunningham BA; McGowan S; Lyras D
Nat Microbiol; 2019 Dec; 4(12):2237-2245. PubMed ID: 31406331
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the peptidoglycan biosynthesis enzymes MurA-F.
Hrast M; Sosič I; Sink R; Gobec S
Bioorg Chem; 2014 Aug; 55():2-15. PubMed ID: 24755374
[TBL] [Abstract][Full Text] [Related]
6. Identification of ClpP Dual Isoform Disruption as an Antisporulation Strategy for Clostridioides difficile.
Bishop CE; Shadid TM; Lavey NP; Kempher ML; Ballard JD; Duerfeldt AS
J Bacteriol; 2022 Feb; 204(2):e0041121. PubMed ID: 34807726
[TBL] [Abstract][Full Text] [Related]
7.
Zhu D; Sorg JA; Sun X
Front Cell Infect Microbiol; 2018; 8():29. PubMed ID: 29473021
[No Abstract] [Full Text] [Related]
8. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
9. Feglymycin is an inhibitor of the enzymes MurA and MurC of the peptidoglycan biosynthesis pathway.
Rausch S; Hänchen A; Denisiuk A; Löhken M; Schneider T; Süssmuth RD
Chembiochem; 2011 May; 12(8):1171-3. PubMed ID: 21538763
[No Abstract] [Full Text] [Related]
10. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Novel Regulator of Clostridioides difficile Cortex Formation.
Touchette MH; Benito de la Puebla H; Alves Feliciano C; Tanenbaum B; Schenone M; Carr SA; Shen A
mSphere; 2021 Jun; 6(3):e0021121. PubMed ID: 34047655
[TBL] [Abstract][Full Text] [Related]
12. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
13. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
[TBL] [Abstract][Full Text] [Related]
14. Avenaciolides: potential MurA-targeted inhibitors against peptidoglycan biosynthesis in methicillin-resistant Staphylococcus aureus (MRSA).
Chang CM; Chern J; Chen MY; Huang KF; Chen CH; Yang YL; Wu SH
J Am Chem Soc; 2015 Jan; 137(1):267-75. PubMed ID: 25521652
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance.
McCoy AJ; Sandlin RC; Maurelli AT
J Bacteriol; 2003 Feb; 185(4):1218-28. PubMed ID: 12562791
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Evaluation of Cephamycin-Based Antisporulation Agents targeting
Cun WY; Bate CE; Srikhanta YN; Hutton ML; Webb CT; Revitt-Mills SA; Lyras D; McGowan S; Yu H; Keller PA; Pyne SG
J Med Chem; 2024 Jan; 67(1):450-466. PubMed ID: 38112278
[TBL] [Abstract][Full Text] [Related]
17. Small-Molecule Inhibition of the
Jones JA; Prior AM; Marreddy RKR; Wahrmund RD; Hurdle JG; Sun D; Hevener KE
ACS Chem Biol; 2019 Jul; 14(7):1528-1535. PubMed ID: 31184849
[No Abstract] [Full Text] [Related]
18. The Potential of Mur Enzymes as Targets for Antimicrobial Drug Discovery.
Kumar D; Sarkar N; Roy KK; Bisht D; Kumar D; Mandal B; Rajagopal M; Dey YN
Curr Drug Targets; 2023; 24(8):627-647. PubMed ID: 37291783
[TBL] [Abstract][Full Text] [Related]
19. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
[TBL] [Abstract][Full Text] [Related]
20. Fate of ingested Clostridium difficile spores in mice.
Howerton A; Patra M; Abel-Santos E
PLoS One; 2013; 8(8):e72620. PubMed ID: 24023628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
